PANGEN BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,000 KRW | -0.83% |
|
+9.49% | -12.79% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 101,239 | 74,917 | 97,864 | 99,783 | 69,405 | 73,462 |
| Enterprise Value (EV) 1 | 88,483 | 67,939 | 97,574 | 94,381 | 68,570 | 75,285 |
| P/E ratio | -21.8 x | -8.38 x | -22.5 x | -28.9 x | -15.4 x | -16.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 17.8 x | 26 x | 15.8 x | 12.6 x | 10.7 x | 10 x |
| EV / Revenue | 15.6 x | 23.6 x | 15.8 x | 11.9 x | 10.5 x | 10.3 x |
| EV / EBITDA | -40.3 x | -10.7 x | -45.8 x | -53.7 x | -23 x | -28.6 x |
| EV / FCF | -14.1 x | -17.1 x | -15.9 x | -21.8 x | -24.2 x | -74.4 x |
| FCF Yield | -7.12% | -5.84% | -6.29% | -4.59% | -4.12% | -1.34% |
| Price to Book | 3.76 x | 4.07 x | 6.89 x | 4.73 x | 4.03 x | 5.85 x |
| Nbr of stocks (in thousands) | 9,642 | 9,642 | 9,642 | 10,672 | 10,678 | 10,678 |
| Reference price 2 | 10,500 | 7,770 | 10,150 | 9,350 | 6,500 | 6,880 |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5,679 | 2,881 | 6,191 | 7,936 | 6,501 | 7,315 |
| EBITDA 1 | -2,196 | -6,324 | -2,132 | -1,756 | -2,987 | -2,629 |
| EBIT 1 | -3,044 | -7,978 | -3,700 | -3,288 | -4,591 | -4,225 |
| Operating Margin | -53.59% | -276.89% | -59.77% | -41.44% | -70.62% | -57.76% |
| Earnings before Tax (EBT) 1 | -1,454 | -8,934 | -4,356 | -3,250 | -4,435 | -4,441 |
| Net income 1 | -4,630 | -8,938 | -4,356 | -3,310 | -4,494 | -4,489 |
| Net margin | -81.52% | -310.19% | -70.36% | -41.71% | -69.13% | -61.36% |
| EPS 2 | -480.9 | -927.0 | -451.8 | -324.1 | -420.9 | -420.4 |
| Free Cash Flow 1 | -6,296 | -3,969 | -6,138 | -4,331 | -2,828 | -1,012 |
| FCF margin | -110.85% | -137.76% | -99.14% | -54.57% | -43.5% | -13.83% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 1,823 |
| Net Cash position 1 | 12,756 | 6,977 | 290 | 5,402 | 835 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.6936 x |
| Free Cash Flow 1 | -6,296 | -3,969 | -6,138 | -4,331 | -2,828 | -1,012 |
| ROE (net income / shareholders' equity) | -15.9% | -39.4% | -26.7% | -18.8% | -23.5% | -30.1% |
| ROA (Net income/ Total Assets) | -4.69% | -11.8% | -6.14% | -5.16% | -8.97% | -12.8% |
| Assets 1 | 98,827 | 75,904 | 71,001 | 64,095 | 50,082 | 35,197 |
| Book Value Per Share 2 | 2,794 | 1,911 | 1,474 | 1,977 | 1,613 | 1,177 |
| Cash Flow per Share 2 | 718.0 | 453.0 | 844.0 | 834.0 | 78.50 | 4.250 |
| Capex 1 | 1,055 | 819 | 756 | 1,425 | 728 | 422 |
| Capex / Sales | 18.58% | 28.43% | 12.21% | 17.96% | 11.2% | 5.77% |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -12.79% | 49.52M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- A222110 Stock
- Financials PanGen Biotech Inc.
